Member Info for draft

50% paycut is a good start.

2021??? Everyone else will have a vaccine by then

Heathrow boss demands mass coronavirus screenings at British airports, including temperature checks, antibody tests and mandatory 'health passports

Maybe we could knock out more than 1 type of test like genedrive

Shareholders in paraytec

Sounds like we have the ability to knock a test out fast

Cellexia is a unique tool for research, breaking down into an open format, perfect for further analysis of captured cells.
Cellexia lends itself to both solid and liquid phase reactions, including in situ hybridisation and single cell PCR, where reagents can be applied and removed with immediate wash steps, in its integrated configuration. Additionally, the ability to generate cell lysates in small volumes from the compartmentalised filter membrane can have numerous applications, including the molecular profiling of circulating tumour cells by PCR or single cell genomics.

There are currently 20 Covid-19 clinical trials listed on the GlobalData Clinical Trials Database that have reported results, and all but two of these trials used biomarkers. Over half of these trials used SAR-CoV-2, and five used Coronavirus Nucleic Acid. Out of these 20 trials, six achieved their endpoints; all six used biomarkers.
Biomarkers can also play a role in understanding how existing drugs can be used to treat Covid-19. The FDA has recently approved a Phase III trial sponsored by Roche that is investigating Actemra (tocilizumab) in Covid-19 patients who have been hospitalised with pneumonia. The drug acts as an interleukin (IL)-6 inhibitor, which interrupts the inflammation response and thus inhibits cytokine release syndrome. Research has shown that IL-6, which can act as a biomarker for increased immune response and inflammation, is more apparent in patients suffering from pneumonia. As the number of Covid-19 trials continues to increase, GlobalData expects that many of these trials will use of biomarkers to help trial progression.

high online sales , handwash for kids and isint inside the INtu centres, its generally outside. and pays a big dividend

yes can you stop harassing them and let them get on with their work

If Aptamer have applied with GSK.Fuji. we know paraytec have applied. Fireworks

Teams behind these projects will then submit these bids to UK Research and Innovation in late 2019, with four to eight of the strongest set to receive between £10m and £50m each to carry out projects designed to drive substantial economic growth.

Looks like something going on - see their tweet - Joint grant application with Aptamer Group in York for a project under the Leeds city Region strengths in Places Fund. Big money at stake there!

will be here to stay because whoever has done goodwill in these bad times will be remembered

Brewdog handwash didn't even get approved by the NHS

Think GSK involved with paraytec a braveheart Investment

The second round of end user trials are underway on Paraytec's Innovate UK funded R&D project ("NEXUS"), which is developing instrumentation for measuring protein aggregation in biopharmaceuticals. Trials have already been conducted with Fujifilm Diosynth and members of Paraytec's scientific team will visit GlaxoSmithKline and Medimmune over the coming weeks. Protein aggregates are an impurity that must be controlled and must stay within product specifications, so measurement is essential to ensure that products containing protein aggregates meet the regulatory requirements.

Doing some apatamer virus testing maybe. Dyor

selling ? - who is that guy again?

shot up to 20p this morning , mms did a smash and grab raid - they got no shares

fireworks here soon

could be due a huge revaluation here cuz most of the BRH portfolio would get revalued now as Covid will have indirectly helped e.g sanitizer sales to NHS

Hopefully back to nominal soon

im well underwater like their plastic bottles in the ocean. why haven't these gusy tried doing recycling for covid ppe and makss

© Oxford Biodynamics
20.12.2019
by ml
The technology of Oxford-based Oxford Biodynamics (OBD) promises insights into why immunotherapies only work in some patients but not in all. A major US pharma company now wants to validate OBD's epigenetic biomarker discovery and development platform causing a share price gain of 15%.


Oxford Biodynamics plc (AIM:OBD) recently presented study results, where researchers profiled blood samples of cancer patients retrospectively with the company's EpiSwitch™ platform. To differentiate responders from non-responders among patients with non-small cell lung cancer or melanoma treated with avelumab (an anti-PD-L1 antibody), pembrolizumab (an anti-PD-1 antibody), or pembrolizumab in combination with a non-platinum chemotherapeutic agent, OBD used machine learning methods to identify relevant epigenetic biomarkers. These kind of biomarkers provide information that can be used to understand various disease states and have the potential to shed light on the impact of treatment to improve clinical outcomes. The study was co-authored with collaborating scientists from German Merck KGaA's US affiliate EMD Serono, US pharma company Pfizer, and US American not-for-profit academic medical center Mayo Clinic.
While Oxford Biodynamics did not reveal in mid-December what major US pharma company entered into a master service agreement with OBD to evaluate EpiSwitch™ biomarkers, it seems likely that industry heavyweight Pfizer is the one interested in finding predictive biomarkers that can help to find better matches of patient and immunotherapy. Under the terms of the master service agreement, the US pharma company will be granted access to OBD’s EpiSwitch™ technology for use in the development of predictive biomarkers. Details of the agreement and financial terms were not disclosed.
Commenting the recently presented study results, Alexandre Akoulitchev, Director and Chief Scientific Officer of Oxford Biodynamics, said that the data show that ”immuno-oncology biomarker development with EpiSwitch yields robust exclusion of non-responders across indications and combinations, provides asset-specific classifiers with high PPV, and may enable immuno-oncology drug development programmes to advance with smaller patient cohorts.”
At London's AIM the share price of OBD rose almost 15% to 118,75 British pence.

A new coronavirus testing lab has opened in Glasgow with the hope that it will be able to carry out tens of thousands of tests a day.
The Lighthouse Laboratory, hosted by the University of Glasgow at their Queen Elizabeth University Hospital Campus, started testing samples for coronavirus this week.
The lab will test samples from the regional test centres where NHS staff and frontline workers with suspected coronavirus are tested.
It is hoped it will quickly move towards processing several thousand tests per day, before scaling up further to tens of thousands of tests per day.
The new facility opened in collaboration with the Scottish Government, industry experts from BioAscent and the University of Dundee, and the Cancer Research UK Beatson Institute.
It is part of what will be the biggest network of diagnostic testing facilities in British history. The Lighthouse Lab project, funded by the UK Government, includes other new sites in Milton Keynes and Alderley Park.
Key worker testing will be carried out at drive-through facilities before samples are assigned and delivered to the closest Lighthouse Lab with capacity.
The Glasgow lab will be staffed on a 24/7 basis by around 100 staff members. More than 800 volunteers came forward to help with the facility, including highly experiences molecular scientists, technicians and bioinformaticians – all with the relevant skills and experience to carry out Covid-19 testing.
Dr Jodie Hay, a Chronic Lymphocytic Leukemia researcher at the University of Glasgow, is one of the volunteers at The Lighthouse Lab in Glasgow.
Dr Hay said: “I was one of the first volunteers selected to begin working in the Lighthouse Lab in Glasgow and it has been incredible to see how quickly everyone has been able to get this lab up and running so that we can begin processing the testing samples.The Glasgow lab will process tests from across the UK but will work to service Scottish tests first as the number taken in the country increases. There are currently three regional testing centres in Glasgow, Aberdeen and Edinburgh.
The new facility is situated in the University of Glasgow’s Clinical Innovation Zone, a space that was designed to meet industrial scale standards and was therefore readily able to be transformed into a testing facility in response to the COVID-19 UK outbreak.
Professor Dame Anna Dominiczak, University of Glasgow Vice Principal and Head of the College of Medical, Veterinary and Life Sciences, who leads the team said: “I am pleased that after weeks of hard work and continued effort by all involved, the University of Glasgow can now deliver the country new, large-scale testing facility, in conjunction with our industry partners and the NHS.

https://www.sundaypost.com/fp/major-new-coronavirus-testing-lab-opens-in-glasgow/